Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer

Apatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control...

Full description

Bibliographic Details
Main Authors: Hui Xia, Cheng Zhou, Zhaoxia Luo, Ping Zhang, Liping Zhu, Zhao Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/full
id doaj-b43d4ed7cfe042b791a97e64231eb565
record_format Article
spelling doaj-b43d4ed7cfe042b791a97e64231eb5652021-04-26T07:06:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.624369624369Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver CancerHui Xia0Cheng Zhou1Zhaoxia Luo2Ping Zhang3Liping Zhu4Zhao Gong5Department of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Dermatology, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaApatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control rate (DCR) in Chinese patients with liver cancer. However, the prevalence of apatinib-induced hand–foot skin reaction (AI-HFSR) is noticeably high. The incidence of AI-HFSR is about 50.5%, of which Grades 1/2 and 3 are 38.8 and 11.6%, respectively. In addition, potential molecular mechanisms underlying the development of AI-HFSR are poorly understood and urgently needed to be investigated histologically. In this review, we summarize and review the current efficacy of apatinib and the prevalence of AI-HFSR in Chinese patients with liver cancer. Besides, we postulate the potential mechanisms underlying the development of AI-HFSR and discuss the optimal clinical management for this unwanted cutaneous side effect.https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/fullapatinibhand–foot skin reactionmechanismsmanagementChinese
collection DOAJ
language English
format Article
sources DOAJ
author Hui Xia
Cheng Zhou
Zhaoxia Luo
Ping Zhang
Liping Zhu
Zhao Gong
spellingShingle Hui Xia
Cheng Zhou
Zhaoxia Luo
Ping Zhang
Liping Zhu
Zhao Gong
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
Frontiers in Oncology
apatinib
hand–foot skin reaction
mechanisms
management
Chinese
author_facet Hui Xia
Cheng Zhou
Zhaoxia Luo
Ping Zhang
Liping Zhu
Zhao Gong
author_sort Hui Xia
title Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
title_short Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
title_full Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
title_fullStr Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
title_full_unstemmed Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
title_sort apatinib-induced hand–foot skin reaction in chinese patients with liver cancer
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-04-01
description Apatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control rate (DCR) in Chinese patients with liver cancer. However, the prevalence of apatinib-induced hand–foot skin reaction (AI-HFSR) is noticeably high. The incidence of AI-HFSR is about 50.5%, of which Grades 1/2 and 3 are 38.8 and 11.6%, respectively. In addition, potential molecular mechanisms underlying the development of AI-HFSR are poorly understood and urgently needed to be investigated histologically. In this review, we summarize and review the current efficacy of apatinib and the prevalence of AI-HFSR in Chinese patients with liver cancer. Besides, we postulate the potential mechanisms underlying the development of AI-HFSR and discuss the optimal clinical management for this unwanted cutaneous side effect.
topic apatinib
hand–foot skin reaction
mechanisms
management
Chinese
url https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/full
work_keys_str_mv AT huixia apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
AT chengzhou apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
AT zhaoxialuo apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
AT pingzhang apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
AT lipingzhu apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
AT zhaogong apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer
_version_ 1721507725604552704